Publicaciones en colaboración con investigadoras/es de Centro de Investigacion Biomedica en Red de Salud Mental (18)

2024

  1. Effects of cannabidiol in post-stroke mood disorders in neonatal rats

    Pediatric Research

2022

  1. Glutamate, Glutamatergic Drugs and Schizophrenia

    Glutamate and Neuropsychiatric Disorders: Current and Emerging Treatments (Springer International Publishing), pp. 493-521

2021

  1. Cannabis and exercise: Effects of Δ9-tetrahydrocannabinol on preference and motivation for wheel-running in mice

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 105

  2. Differential brain ADRA2A and ADRA2C gene expression and epigenetic regulation in schizophrenia. Effect of antipsychotic drug treatment

    Translational Psychiatry, Vol. 11, Núm. 1

  3. Opposite alterations of 5­HT2A receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile

    Translational Psychiatry, Vol. 11, Núm. 1

  4. Sex-dependent pharmacological profiles of the synthetic cannabinoid MMB-Fubinaca

    Addiction Biology, Vol. 26, Núm. 3

  5. Subcellular specificity of cannabinoid effects in striatonigral circuits

    Neuron, Vol. 109, Núm. 9, pp. 1513-1526.e11

  6. α2A- and α2C-adrenoceptor expression and functionality in postmortem prefrontal cortex of schizophrenia subjects

    European Neuropsychopharmacology, Vol. 52, pp. 3-11

2020

  1. Long-term hippocampal interneuronopathy drives sex-dimorphic spatial memory impairment induced by prenatal THC exposure

    Neuropsychopharmacology, Vol. 45, Núm. 5, pp. 877-886

2019

  1. Endocannabinoid system imbalance in the postmortem prefrontal cortex of subjects with schizophrenia

    Journal of Psychopharmacology, Vol. 33, Núm. 9, pp. 1132-1140

  2. Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via Gαi1-proteins

    European Neuropsychopharmacology, Vol. 29, Núm. 12, pp. 1453-1463

  3. The motivation for exercise over palatable food is dictated by cannabinoid type-1 receptors

    JCI Insight, Vol. 4, Núm. 5

2018

  1. The endocannabinoid system in mental disorders: Evidence from human brain studies

    Biochemical Pharmacology, Vol. 157, pp. 97-107

2017

  1. Antipsychotic-induced Hdac2 transcription via NF-ΰ B leads to synaptic and cognitive side effects

    Nature Neuroscience, Vol. 20, Núm. 9, pp. 1247-1259

2016

  1. Group II metabotropic glutamate receptors as targets for novel antipsychotic drugs

    Frontiers in Pharmacology, Vol. 7, Núm. MAY

2013

  1. Antidepressant-like properties of three new α2-adrenoceptor antagonists

    Neuropharmacology, Vol. 65, pp. 13-19

  2. Dysregulated 5-HT2A receptor binding in postmortem frontal cortex of schizophrenic subjects

    European Neuropsychopharmacology, Vol. 23, Núm. 8, pp. 852-864

  3. Quantification of endocannabinoids in postmortem brain of schizophrenic subjects

    Schizophrenia Research, Vol. 148, Núm. 1-3, pp. 145-150